Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.55 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3859907 | 0.82 | HRH3 (0.51) | HRH3 | |
| SCHEMBL3767559 | 0.82 | IRAK4 (0.49) | HRH3DRD2DRD3HTR1AOPRM1 | |
| SCHEMBL15918310 | 0.81 | GRIN2B (0.49) | HRH3DRD2DRD3GRIN2BCXCR3 | |
| SCHEMBL17667869 | 0.81 | GRIN2B (0.49) | HRH3DRD2DRD3GRIN2BCXCR3 | |
| SCHEMBL30582911 | 0.80 | HRH3 (0.52) | HRH3ALOX15DRD2DRD3GRIN2B | |
| SCHEMBL22668979 | 0.80 | GRIN2B (0.48) | HRH3ALOX15DRD2DRD3GRIN2B | |
| SCHEMBL4603963 | 0.78 | HRH3 (0.50) | HRH3ALOX15DRD2DRD3GRIN2B | |
| SCHEMBL1351805 | 0.78 | HTR3E (0.60) | HRH3ALOX15DRD2DRD3GRIN2B | |
| SCHEMBL18427064 | 0.77 | BPTF (0.46) | HRH3DRD2DRD3GRIN2BPHGDH | |
| Hydrochloric Acid SCHEMBL5220893 | 0.77 | HTR3E (0.59) | HRH3ALOX15DRD2DRD3GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | HRH3 1/4885KDM2B 1203/4885GAA 2437/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | HRH3 1/4885KDM2B 1203/4885GAA 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.